Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
NCT ID: NCT00605267
Last Updated: 2012-09-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
197 participants
INTERVENTIONAL
2007-10-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
NCT00295646
Zoladex Plus Tamoxifen in Breast Cancer
NCT00827307
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT00287534
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
NCT00235937
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
NCT00186121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Tamoxifen
Tamoxifen
20 mg once daily oral dose
Goserelin acetate (Zoladex)
3.6mg/month depot injection
2
Anastrazole (Arimidex)
Anastrazole (Arimidex)
1 mg once daily oral dose
Goserelin acetate (Zoladex)
3.6mg/month depot injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tamoxifen
20 mg once daily oral dose
Anastrazole (Arimidex)
1 mg once daily oral dose
Goserelin acetate (Zoladex)
3.6mg/month depot injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Toshiyuki Kihara
Role: STUDY_DIRECTOR
Clinical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Hakata, Fukuoka, Japan
Research Site
Kumamoto, Kumamoto, Japan
Research Site
Nagoya, Nagoya, Japan
Research Site
Osaka, Osaka, Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012 Apr;13(4):345-52. doi: 10.1016/S1470-2045(11)70373-4. Epub 2012 Jan 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D539BC00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.